Bayer Adds Sleep Data to Lynkuet's Label Story as Asundexian Clears China

Bayer shares closed Wednesday at €45.65, up 3.9%, after the drugmaker delivered two pieces of pharmaceutical news: a Chinese approval for its stroke-prevention candidate Asundexian and positive interim results for Nubeqa in prostate cancer. A third announcement — exploratory sleep analyses for its menopause therapy Lynkuet — rounded out the week but carries a different weight for investors.

Sleep Benefit Remains Descriptive, Not Confirmatory

Bayer presented the Lynkuet findings at the annual meeting of the Menopause Society, drawing on pooled data from the Phase III OASIS-1 and OASIS-2 trials. The studies enrolled 796 women with moderate-to-severe vasomotor symptoms during menopause.

Among participants taking Lynkuet, the share reporting poor or very poor sleep quality fell from 66.6% at baseline to 20.5% by week 12. In the placebo arm, the corresponding proportion dropped from 57.8% to 38.7%. The two groups thus began from different starting levels, and Bayer analyzed the individual sleep reports descriptively only — no formal statistical hypothesis testing was performed. The results may also not translate to patients in routine care.

Lynkuet, whose active ingredient is Elinzanetant, is approved for moderate-to-severe menopausal vasomotor symptoms. The sleep analysis does not extend that label to the treatment of sleep disorders, and the drug is contraindicated in pregnancy. Safety data came from three studies covering 1,420 women, with the OASIS-3 extension running up to 52 weeks.

For investors, the release mainly enriches the clinical profile of an already-approved product. It describes an aspect relevant to patients but supports no claims about additional revenue or a broader label.

Asundexian's China Green Light

The Chinese approval for Asundexian covers reduction of stroke risk following a non-cardioembolic ischemic stroke or high-risk TIA. The drug was cleared there under the brand name Sunharbo, and Bayer describes it as the world's first approved FXIa inhibitor. According to the Wall Street Journal, the company hopes the drug will offset revenue losses after the patent expiry of Xarelto.

Nubeqa's Interim Readout

In the interim analysis of the Phase III DASL-HiCaP study, Nubeqa reduced the risk of metastases or death by 58% after a median observation period of 3.8 years. The combined endpoint covers the occurrence of metastases or death. Nubeqa was given alongside ADT and radiotherapy, with the comparator arm receiving placebo plus ADT and radiotherapy; the reported risk reduction applies to that comparison.

Metastasis-free survival at four years reached 95% in the Nubeqa arm versus 88% in the control group, giving Bayer both a relative risk figure and survival rates at a defined time point.

The three announcements sit at different stages of development. Asundexian's is a granted approval for a defined patient population in China; Nubeqa's rests on an interim analysis; and Lynkuet's is a supplementary, exploratory evaluation of an approved medicine — closer to a richer product profile than to a new authorization or a statistically confirmed proof of extra efficacy. Bayer's next scheduled reporting date is the release of third-quarter 2026 results on November 3, 2026.